Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2

Daruka Mahadevan, Carla Morales, Laurence S. Cooke, Ann Manziello, David W. Mount, Daniel O. Persky, Richard I. Fisher, Thomas P. Miller, Wenqing Qi

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Keyphrases